Petros Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Accounts Receivable of -$1.82 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was -$1.56M.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $214.01K, a 49.80% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was -$154.71K, a 206.42% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was -$320.27K, a 198.36% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$1.82M, a 1361.79% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $144.13K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$515.96K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$2.55M, a 192.67% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.34M derived: sum of 2 quarters · filed 2025-03-31 | -$1.50M derived: sum of 3 quarters · filed 2025-03-31 | -$1.82M 10-K · filed 2025-03-31 |
| 2024-09-30 | $214.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $59.31K derived: sum of 2 quarters · filed 2024-11-13 | -$260.96K 10-Q · filed 2024-11-13 | -$1.01M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$154.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$474.97K 10-Q · filed 2024-08-14 | -$1.23M derived: sum of 3 quarters · filed 2025-03-31 | -$801.82K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$320.27K 10-Q · filed 2024-05-15 | -$1.07M derived: sum of 2 quarters · filed 2025-03-31 | -$647.12K derived: sum of 3 quarters · filed 2025-03-31 | -$501.75K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$753.16K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$326.85K derived: sum of 2 quarters · filed 2025-03-31 | -$181.48K derived: sum of 3 quarters · filed 2025-03-31 | $144.13K 10-K · filed 2025-03-31 |
| 2023-09-30 | $426.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $571.67K derived: sum of 2 quarters · filed 2024-11-13 | $897.29K 10-Q · filed 2024-11-13 | -$792.77K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $145.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $470.98K 10-Q · filed 2024-08-14 | -$1.22M derived: sum of 3 quarters · filed 2024-08-14 | -$3.23M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $325.61K 10-Q · filed 2024-05-15 | -$1.36M derived: sum of 2 quarters · filed 2024-05-15 | -$3.38M derived: sum of 3 quarters · filed 2024-05-15 | -$1.36M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$3.70M derived: sum of 2 quarters · filed 2024-04-01 | -$1.69M derived: sum of 3 quarters · filed 2024-04-01 | -$515.96K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $4.08K derived: sum of 2 quarters · filed 2023-11-15 | $1.17M 10-Q · filed 2023-11-15 | $1.75M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.19M 10-Q · filed 2023-08-14 | $3.76M derived: sum of 3 quarters · filed 2023-08-14 | $3.75M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.17M 10-Q · filed 2023-05-15 | $1.75M derived: sum of 2 quarters · filed 2023-05-15 | $1.74M derived: sum of 3 quarters · filed 2023-05-15 | -$2.42M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $576.90K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $565.61K derived: sum of 2 quarters · filed 2023-03-31 | -$3.59M derived: sum of 3 quarters · filed 2023-03-31 | -$2.55M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$11.28K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$4.17M derived: sum of 2 quarters · filed 2022-11-15 | -$3.13M 10-Q/A · filed 2022-11-15 | -$1.92M derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | -$4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$3.11M 10-Q · filed 2022-08-12 | -$1.91M derived: sum of 3 quarters · filed 2022-08-12 | $1.13M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.04M 10-Q · filed 2022-05-16 | $2.25M derived: sum of 2 quarters · filed 2022-05-16 | $5.29M derived: sum of 3 quarters · filed 2022-05-16 | $2.31M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $4.24M derived: sum of 2 quarters · filed 2022-03-31 | $1.27M derived: sum of 3 quarters · filed 2022-03-31 | $2.75M 10-K · filed 2022-03-31 |
| 2020-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $68.97K derived: sum of 2 quarters · filed 2021-11-15 | $1.55M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$1.49M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $1.48M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |